Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results Total of 509 Patients Enrolled in Confirmatory Late-stage Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2b/3 Clinical Trial in Patients with Alzheimer’s Disease Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73 (blarcamesine) Phase 2/3 AVATAR Clinical Trial in Patients with Rett Syndrome…